Month: September 2026

MONTREAL, Sept. 15, 2026 (GLOBE NEWSWIRE) — NanoXplore Inc. (“NanoXplore” or “the Corporation”) (TSX: GRA and OTCQX: NNXPF), a world-leading graphene company, reported its financial results today for the year ended June 30, 2026.

All amounts in this press release are in Canadian dollars, unless stated otherwise.

KEY FINANCIAL HIGHLIGHTS Q4-2026

• Total revenues of $33,905,991 compared to $31,685,923 last year, representing a 7% increase;
• Adjusted gross margin⁽¹⁾ on revenues from customers of 22.5% compared to 24.7% last year;
• Loss of $1,568,324 compared to a loss of $2,295,472 last year;
• Adjusted EBITDA⁽²⁾ of $1,908,431 compared to $2,475,379 last year;
• Adjusted EBITDA⁽²⁾ of $2,049,773 compared to $2,697,655 last year for the Advanced Materials, Plastics and Composite Products segment;
• Adjusted EBITDA⁽²⁾ loss of $141,342 compared to $222,276 last year for the Battery Cells and Materials segment;
• Total liquidity of $30,048,438 as at June 30, 2026, including cash and cash equivalents of $25,048,438;
• Total long-term debt of $10,554,435 as at June 30, 2026, higher by $6,241,511 compared to June 30, 2025.

KEY FINANCIAL HIGHLIGHTS FISCAL YEAR 2026

• Total revenues of $117,276,309 compared to $128,918,388 last year, representing a 9% decrease;
• Adjusted gross margin⁽¹⁾ on revenues from customers of 21.3% compared to 22.3% last year;
• Loss of $11,827,981 compared to a loss of $9,657,120 last year;
• Adjusted EBITDA⁽²⁾ of $1,922,206 compared to $6,122,283 last year;
• Adjusted EBITDA⁽²⁾ of $2,149,114 compared to $6,847,826 last year for the Advanced Materials, Plastics and Composite Products segment;
• Adjusted EBITDA⁽²⁾ loss of $226,908 compared to $725,543 last year for the Battery Cells and Materials segment.

FINANCIAL OUTLOOK

Based on the visibility we have today and the various initiatives in progress or that will begin to produce returns during the year, we anticipate total revenues for fiscal year 2027 between $130M and $140M. In addition, we expect revenues for fiscal year 2028 between $160M and $170M.   

OVERVIEW

Rocco Marinaccio, President & Chief Executive Officer, stated: “After a challenging start to the year, I am pleased overall with our fiscal year 2026 performance.  During the year, we had to mitigate significant volume drop by adjusting our operating cost structure while also launching new programs, managing material price increases and setting up a new plant. The entire team delivered great results in a challenging context. Fiscal year 2026 was also a transformative year for NanoXplore. We are in the strongest position we have ever been as a Company — a solid balance sheet, a robust $35 million pipeline of graphene-enhanced Solutions business launching over the next 18 months, and an innovative new product launch in our D Series graphene that is opening entirely new, high-margin markets for the Corporation. In the past year we launched our state-of-the-art facility in Statesville, North Carolina, supplying Club Car, formalized our partnership with Chevron Phillips Chemical, supplying an innovative lubricant additive for the oil and gas industry, and achieved our best safety record in Company history, reducing our total recordable injury frequency by two-thirds. Looking ahead, we see high-margin opportunities commercializing in fiscal year 2027 across insulating foams, thin films, and drilling fluids. We have also sharpened VoltaXplore’s strategy around the market where our cell technology is most differentiated and where we can capture the most value: supplying high-performance cells to defence and other high-power, high-energy applications such as UAVs — a fast-growing North American market with very few domestic suppliers. Combined with the stability of our graphene-enhanced Solutions business, we anticipate fiscal 2027 revenue growth between 11-20%, with revenues between $130 million and $140 million, and expect to deliver positive free cash flow — which would represent record highs for NanoXplore.”

⁽¹⁾ Adjusted gross margin is a non-IFRS measure and a reconciliation can be found in the “Overall Results” section.
⁽²⁾ Adjusted EBITDA is a non-IFRS measure and a reconciliation can be found in the “Overall Results” section.

BUSINESS UPDATE

During the year ended June 30, 2026, the Corporation continued to focus on developing markets for its graphene products as well as downstream pre-mixed additives, masterbatches, concentrates and products that facilitate customer adoption. In this regard, the Corporation has been successful integrating GrapheneBlack^® into multiple product streams, both internally and externally, and has also advanced its D-Series dry-processed graphene platform for applications where different graphene characteristics are required. Through this market development work, the Corporation has determined that a single graphene product is not expected to deliver optimal performance across all applications, and that tailoring graphene characteristics to specific end-use requirements is an important differentiator of its manufacturing platform. The Corporation continues to engage with potential customers who are validating GrapheneBlack^®, D-Series graphene, and related graphene-enhanced masterbatches, concentrates, and products.

Commercial Update

Drilling fluids

On September 18, 2025, the Corporation announced the signing of a multi-year supply agreement with Chevron Phillips Chemical Company (“CP Chem”) for the sale of TriboGraf^®, the Corporation’s proprietary carbon product used as a formulation additive in drilling fluids to increase lubricity. This was the culmination of over 18 months of collaborative work between the companies through lab tests and well trials that produced exceptional results by significantly reducing costs to the operators by saving approximately 20% drilling time and wear on drilling equipment. This formulation is marketed by CP Chem as NanoSlide^®.

Following the exceptional performance of NanoSlide^® in well trials, CP Chem initially expected near-term commercial activity that would have resulted in additional product shipments by the Corporation. However, CP Chem subsequently advised the Corporation that the anticipated customer opportunity did not proceed because CP Chem lost a major customer due to customer-specific commercial considerations unrelated to the performance of NanoSlide^®. As a result, the timing of additional product shipments by the Corporation has shifted to the qualification and adoption timelines of CP Chem’s broader prospective customer base. As of the date of this MD&A, CP Chem has shipped NanoSlide^® samples to multiple prospective customers for evaluation, and all customers that have completed laboratory testing have confirmed that NanoSlide^® performs as intended. These results continue to support the technical value proposition demonstrated during the initial well trials. The next phase of customer evaluation involves well trials, which are the key determinant in advancing toward commercial adoption. Although commercialization has progressed more slowly than initially anticipated due to the loss of this initial customer opportunity, CP Chem and NanoXplore remain confident that NanoSlide^® is a high-performance, cost-effective lubricant with significant market potential. As prospective customers continue to advance through testing and qualification, the companies believe NanoSlide^® remains well positioned for broader market adoption.

Insulating foams

Several years ago, the Corporation initiated a development program with a Fortune 500 producer of insulating foam products to enhance thermal insulation performance through the incorporation of graphene. The formulation is currently being optimized ahead of final plant trials anticipated in early 2027. Insights gained through this collaboration have enabled the Corporation to expand its market development activities across the insulating foam sector, resulting in ongoing projects with leading manufacturers that collectively account for approximately 80% of the North American market.

Some of these programs are expected to commercialize during fiscal year 2027. One major customer intends to replace its current additive in some of its products with the Corporation’s product and is currently finalizing approvals to begin purchasing volumes for an immediate conversion. Based upon the customer’s preliminary demand indications, the Corporation anticipates approximately 1,000 MT per year of masterbatch, at a 30% graphene loading, in the first full year of production with the potential for additional volume growth thereafter.

Additionally, the Corporation recently signed a Letter of Intent (“LOI”) with a leading global material supplier in the field of polyurethane (“PU”) foams. Pursuant to the term of the LOI, this partner is expected to purchase graphene powder from the Corporation and produce shelf-stable graphene dispersions in polyol, which are used in the manufacture of PU foams. This partner maintains an extensive customer base across the United States and Europe and has helped identify a significant opportunity in the European foam market, where graphene may reduce or replace a commonly used halogenated flame retardant that is facing increasing regulatory scrutiny as the market transitions toward more sustainable and non-halogenated alternatives.

Industrial and Consumer plastic films

On June 15, 2026, the Corporation announced a technical innovation in partnership with Techmer PM LLC (“Techmer”), its longstanding partner on graphene enhancements for plastics.

Industrial plastic films encompass landscape liners, protective films, pallet wraps, heavy-duty plastic bags and other industrial liners. Consumer plastic films encompass trash bags and a variety of (non-food) consumer packaging. These applications represent a substantial addressable market for graphene-enhanced materials, given the scale of film production and the industry’s ongoing focus on material reduction, recycled content and improved product performance.

This innovation has demonstrated more than 70% improvement in mechanical strength and may enable film producers to reduce film thickness by up to 20% while maintaining tensile, tear, and puncture performance. The innovation also has the potential to increase the amount of recycled content that can be incorporated into film formulations without sacrificing performance, a critical advancement for packaging manufacturers navigating increasingly stringent sustainability mandates and circular economy targets. The performance improvements observed to date are believed to result from the distinctive properties of the Corporation’s dry-processed graphene (D-Series), which has shown significantly greater benefits in these applications as compared to liquid-phase-processed graphene materials (X-Series).

Techmer’s broad and diversified customer base provides the Corporation with immediate access to a wide range of potential applications within the industry. Following the announcement in June 2026, several of Techmer’s customers have requested and received samples for testing and evaluation. The Corporation expects a number of these opportunities to advance through the qualification process in the coming months, which could support commercial adoption. Accordingly, the Corporation currently anticipates graphene orders to begin in the second half of fiscal year 2027.

The global plastic bag industry is a multi billion-dollar market and represents a meaningful opportunity for the Corporation to increase graphene adoption in plastic film applications. The Corporation continues to work with industry participants, including leading brands such as Hefty and Glad, to demonstrate the performance advantages that graphene can provide in high-volume film applications.

While the inclusion rate of graphene in these applications is typically less than 1%, the associated selling price per kilogram is substantially higher than many of the Corporation’s existing graphene products. Accordingly, successful commercialization of these applications could provide access to high-volume end markets while generating a higher margin profile relative to the Corporation’s traditional graphene product portfolio.

Conductive graphene

On May 5, 2026, the Corporation announced the launch of xGnP™ D500-HP, a high-purity graphene powder engineered for highly conductive applications, including energy storage, conductive composites, advanced electronics and other applications where carbon black is currently a dominant conductive additive. D500-HP demonstrates the strength of the Corporation’s graphene manufacturing platform and Corporation’s ability to tailor graphene characteristics to the requirements of specific end-use applications. Through its development work, the Corporation has determined that different applications may require graphene materials with different characteristics, and that a single graphene product is not expected to deliver optimal performance across all target markets. For example, the Corporation’s X-series GrapheneBlack^® product did not provide the level of conductivity required for certain highly conductive applications, leading to the development of D500-HP for these markets.

The Corporation currently sells conductive graphene to an Asian customer and is working with several others on commercial opportunities that are expected to materialize over the course of the coming fiscal year. In these applications, graphene may be used on its own or in combination with carbon black, where even partial replacement of carbon black has the potential to deliver enhanced conductivity, mechanical performance or other functional benefits. Products serving this market command a wide range of selling prices depending on performance requirements and specifications and are expected to generate a higher margin profile relative to the Corporation’s traditional graphene product portfolio. As a result, successful commercialization in conductive applications could represent a meaningful growth opportunity for the Corporation, particularly in energy storage and other markets requiring high-performance conductive materials.

Graphene-enhanced molded thermoplastics

On November 12, 2025, the Corporation announced the award and start of production of molded thermoplastic parts for Club Car LLC (“Club Car”). This new customer in the recreational products market provides diversification from the transportation industry. Based on historical program performance in this market, the Corporation expects to benefit from a relatively stable and predictable level of annual demand going forward. The success of this program has also created additional opportunities within the recreational products market, and the Corporation is currently engaged in discussions with other potential customers regarding prospective commercial opportunities.

Since the end of fiscal Q1-2026, sales volumes for Paccar and Volvo have steadily increased. While volume levels remain below fiscal years 2024 and 2025, they continue to increase and provide NanoXplore with steadily increasing revenue. New Volvo programs awarded to the Corporation and expected to start part production in the second half of fiscal year 2027 have been delayed by Volvo and are now expected to begin during fiscal year 2028. The Corporation expects to generate annual revenue of approximately $25M at mature volumes from these 2 programs.

In January 2026, the Corporation was awarded a new program from Volvo to produce sheet molded compound parts (“SMC”) with expected annual revenues of $9-10M at mature volumes. This award includes tooling revenues which began recognition this past quarter and are expected to conclude in late fiscal 2027 or early fiscal 2028 with part production expected to start during fiscal year 2028. The Corporation intends to produce the part with graphene-enhanced SMC material.

Graphene-enhanced recycled plastics
        
Recycled plastics are an increasingly important input for industrial and consumer products as customers respond to sustainability mandates, circular-economy targets, and demand for lower-emission materials. The recycling process inherently degrades the mechanical performance of the polymer. The addition of graphene can restore these lost properties, allowing recycled content to be used in applications that would otherwise require virgin resin. Both post-consumer and post-industrial recycled streams can benefit from the addition of graphene. This capability benefits the Corporation directly through its subsidiary, Canuck Compounders Inc., which supplies recycled compounds, as well as external customers seeking to increase recycled content in their products without sacrificing performance.

The addition of the Corporation’s dry-processed graphene (D-series) has created additional opportunities in this area. Certain applications that were not previously achievable, based on their technical requirements, are now possible using dry-processed graphene. From the outset of conversations with Club Car, the intent was not only to supply parts but ultimately to convert certain products to graphene-enhanced recycled compounds. The Corporation is currently working with Club Car on formulations with the goal of matching or exceeding the performance and quality of the current product. The Corporation expects conversion to graphene-enhanced recycled compounds to begin in early calendar 2027 with our graphene and recycled compounds from Canuck Compounders.

Finally, developments in graphene-enhanced recycled compounds since the acquisition of Canuck Compounders is expected to replace carbon black in the majority of the product offerings, improving mechanical performance while supporting customers’ sustainability objectives.

VoltaXplore Update

VoltaXplore Inc. is a wholly owned subsidiary of the Corporation. Through VoltaXplore, the Corporation manufactures silicon-based, graphene-enhanced lithium-ion battery cells. VoltaXplore operates a 1 MWh cylindrical battery production facility in Montréal, Québec, producing cells in the 21700 format. The cells are designed for high energy density and high-power applications to address the common stability and cycle life challenges associated with high-silicon anodes. Additionally, the recently improved tab configuration reduces the internal resistance of the cell, supporting both high-power and high-energy performance. VoltaXplore can adjust cell design and materials to meet specific customer energy-storage requirements.

During the year, management undertook a strategic review of VoltaXplore and refocused the business on validated near-term market opportunities in drone and defence applications. Consistent with the Corporation’s capital-protection discipline and capital-allocation objectives, VoltaXplore has been restructured to operate under a specialty model focused on selected target markets. The repositioning is supported by growing demand for domestically produced battery cells driven by trade and geopolitical developments, as well as the procurement preferences and requirements for Canadian-manufactured products.

The repositioning represents a shift from VoltaXplore’s earlier focus on electric-vehicle applications toward defence and dual-use platforms. Targeted end markets include UAVs, UGVs, portable electronics, and other applications serving Canadian and U.S. defence customers.

VoltaXplore’s existing production capability has enabled it to begin supplying cells to interested parties for testing and qualification. VoltaXplore’s technology development has been supported by contributions under federal programs, including Natural Resources Canada’s Energy Innovation Program and the National Research Council of Canada’s Industrial Research Assistance Program (“IRAP”), both of which remain active.

For fiscal 2027, VoltaXplore intends to continue pursuing additional grants and subsidies. It is also seeking to leverage its Canadian operations in order to supply the Canadian Armed Forces, the Department of National Defence (DND), and other Government of Canada purchasers, either directly or through its partners and customers, typically module and pack manufacturers, with whom letters of intent have been executed.

Strategic and investment plan update

During Q4 of fiscal year 2026, the Corporation completed its investments previously outlined in November 2022.
As part of its strategic and investment plan:

1) During fiscal year 2024, the Corporation was awarded three programs from two existing customers, one large commercial vehicle OEM and one industrial equipment manufacturer, to supply exterior parts of vehicles. These components are used in both internal combustion engines and electric vehicles. Production for the first program started during the summer of 2025 in our Newton, NC plant while the start of production for the other two programs is planned for fiscal year 2028. These programs generally last for a period of 10 years.

2) During fiscal year 2024, the Corporation was asked by one of our customers to expand its Saint-Clotilde-de-Beauce facility to allow for a capacity expansion of a graphene-enhanced part we currently supply. This expansion was completed in May 2025. The expansion was mostly paid for by our customer but while volumes during fiscal year 2026 have increased, the capacity currently remains underutilized. The expansion costs were approximately $8M, of which $5M was paid by the customer. 

3) Part of the strategic plan is the active anode materials (“CSPG”) and dry-process graphene initiative. The objective of CSPG production was to create a graphite waste stream that would be financially beneficial for ultra low-cost graphene production. Despite having obtained financial support intentions from both Provincial and Federal governments, the changes over the last year in the economic and geopolitical landscape have caused a reduction in the financial viability of such an investment interest from potential customers to enter into binding agreements. In January 2026, the Corporation made the strategic decision to not pursue this part of the initiative and focus solely on dry-process graphene. Instead, the Corporation has chosen to explore alternative sources for waste-stream graphite that could potentially be available in North America in the future. This new direction will avoid an estimated $100M investment while still securing low-cost graphite by-product ideal for ultra low-cost dry-process graphene production.

4) In September 2025, the Corporation started a new lease for a plant in Statesville, NC as part of the US expansion of graphene-enhanced composite parts manufacturing and began generating sales in October 2025.

R&D Improvement: Large-Scale Dry Process Manufacturing

During the fiscal year ended June 30, 2026, the Corporation continued to advance the development and scale-up commissioning of its novel dry-exfoliation manufacturing process. The resulting dry-exfoliated products, branded GrapheneBlack xGnP™ D-Series, are intended to address markets that are largely complementary to those served by the Corporation’s liquid-phase exfoliation products (X-Series), with limited overlap in application.

Based on management’s current estimates, the dry process is expected to require approximately 40% less capital expenditure and approximately one-quarter of the floor space required for an equivalent liquid-phase facility.

The Corporation reported the installation of one production module for dry-process graphene. The mechanical and electrical work has been completed on schedule and within budget. Depending on product grade, the line is designed to deliver annual production capacity of up to 1,000 tonnes.

The dry process eliminates several manufacturing steps required in liquid-phase production, including washing and drying. Management believes this simpler manufacturing sequence, combined with reduced water consumption, may result in lower unit production costs for certain grades of D-Series products and a reduced environmental footprint relative to the liquid-phase process. These cost reductions are expected to bring the Corporation’s production costs closer to those of traditional carbon additives, such as specialty carbon blacks.

The underlying technology is protected by several granted patents held by the Corporation. In internal testing, D-Series graphene has improved certain physical properties of polymers, including electrical conductivity and mechanical properties. Potential end-use applications identified by management include energy storage, recycled plastics, packaging, insulation foams, lightweight composites, plastic pipes, and geosynthetics. Commercial adoption in any of these applications remains subject to customer qualification and validation.

During the period, the Corporation continued sampling D-Series graphene with new and existing customers and advanced product validation activities, including the production of plastic masterbatches and compounds incorporating D-Series graphene and the testing of their mechanical, electrical, and other physical properties. Results to date indicate improved performance relative to currently produced grades in certain target markets, at a lower cost to end users. Management believes these attributes may, if confirmed through final customer qualification, accelerate the adoption of graphene and shorten the sales cycle in markets that were not previously addressable with the X-Series product line.

Financing

On October 30, 2025, the Corporation completed a financing by way of a bought deal private placement of 10,720,350 common shares at a price of $2.40 per share for gross proceeds of $25,728,840. The aggregate issuance costs related to this issuance, including the commission, were $1,441,343 and paid in cash.

The Corporation intends to use the net proceeds raised from the Offering to support future growth by investing in dry-process graphene expansion, and for general corporate and working capital purposes.

CEO Succession Plan

On December 4, 2025, Soroush Nazarpour stepped down from his functions as President and Chief Executive Officer and was re-elected to the Board of Directors, at the annual general meeting. Rocco Marinaccio, the Corporation’s Chief Operating Officer, has succeed Mr. Nazarpour as President and Chief Executive Officer on the same date. On February 27, 2026, Mr. Nazarpour tendered his resignation to the Board of Directors.

Other Updates

In August 2025, the Corporation was selected to receive up to $2,750,000 over the next 3 years from Natural Resources Canada under the Energy Innovation Program’s Battery Industry Acceleration call for proposals for the research and development on the use of Silicon Graphene in ultra-high-power cylindrical battery cells. In April 2026, this amount was increased by approximately $700,000 for a total of $3,450,000.

* NON-IFRS MEASURES

The Corporation prepares its financial statements under IFRS. However, the Corporation considers certain non-IFRS financial measures as useful additional information in measuring the financial performance and condition of the Corporation. These measures, which the Corporation believes are widely used by investors, securities analysts and other interested parties in evaluating the Corporation’s performance, do not have a standardized meaning prescribed by IFRS and therefore may not be comparable to similarly titled measures presented by other publicly traded companies, nor should they be construed as an alternative to financial measures determined in accordance with IFRS. Non-IFRS measures include “Adjusted EBITDA” and “Adjusted gross margin”.

The following tables provide a reconciliation of IFRS “Loss” to Non-IFRS “Adjusted EBITDA” and of IFRS “Gross margin” to Non-IFRS “Adjusted Gross margin” for the years ended June 30, 2026 and 2025.

IFRS “Loss” to Non-IFRS “Adjusted EBITDA”

		Q4-2026			Q4-2025			FY 2026			FY 2025
		$			$			$			$
Loss		(1,568,324		)	(2,295,472		)	(11,827,981		)	(9,657,120		)
Current and deferred income tax expenses (recovery)		107,782			74,950			(1,130,561		)	310,881
Net interest expenses		716,872			131,397			2,103,169			426,882
Foreign exchange		(939,678		)	(247,986		)	(1,013,231		)	417,130
Share-based compensation expenses		335,753			251,878			1,304,040			1,435,365
Non-operational items (1)		99,000			1,600,000			68,000			1,870,000
Depreciation and amortization		3,157,026			2,960,612			12,418,770			11,319,145
Adjusted EBITDA		1,908,431			2,475,379			1,922,206			6,122,283
– From Advanced Materials, Plastics and Composite Products		2,049,773			2,697,655			2,149,114			6,847,826
– From Battery Cells and Materials		(141,342		)	(222,276		)	(226,908		)	(725,543		)

_{⁽¹⁾ Non-operational items consist of professional fees mainly due to debt renegotiation and to prospectuses related fees.}

IFRS “Gross margin” to Non-IFRS “Adjusted Gross margin”

	Q4-2026	Q4-2025	FY 2026	FY 2025
	$	$	$	$
Revenues from customers	33,466,068	31,159,203	115,037,976	126,363,218
Cost of sales	25,938,601	23,451,384	90,505,840	98,183,546
Adjusted gross margin	7,527,467	7,707,819	24,532,136	28,179,672
Depreciation (production)	1,984,585	1,801,653	8,189,037	6,817,138
Gross margin	5,542,882	5,906,166	16,343,099	21,362,534

REPORTING SEGMENTS RESULTS

NanoXplore reports its financials in two distinct segments: Advanced Materials, Plastics and Composite Products and Battery Cells and Materials.

	Q4-2026		Q4-2025		Variation				FY 2026		FY 2025		Variation
	$		$		$		%		$		$		$		%
From Advanced Materials, Plastics and Composite Products
Revenues	33,657,785		31,578,291		2,079,494		7	%	116,137,935		128,243,848		(12,105,913	)	(9	%)
Non-IFRS Measure *
Adjusted EBITDA	2,049,773		2,697,655		(647,882	)	(24	%)	2,149,114		6,847,826		(4,698,712	)	(69	%)
From Battery Cells and Materials
Revenues	248,206		107,632		140,574		131	%	1,138,374		674,540		463,834		69	%
Non-IFRS Measure*
Adjusted EBITDA	(141,342	)	(222,276	)	80,934		36	%	(226,908	)	(725,543	)	498,635		69	%

A. RESULTS OF OPERATIONS VARIANCE ANALYSIS – THREE-MONTH PERIODS

Revenues

	Q4-2026	Q4-2025	Variation				Q3-2026	Variation
	$	$	$		%		$	$		%
Revenues from customers	33,466,068	31,159,203	2,306,865		7	%	31,656,876	1,809,192		6	%
Other income	439,923	526,720	(86,797	)	(16	%)	690,501	(250,578	)	(36	%)
Total revenues	33,905,991	31,685,923	2,220,068		7	%	32,347,377	1,558,614		5	%

All revenues are coming from the Advanced Materials, Plastics and Composite Products segment, except for $248,206 of revenues from Other income [Q4-2025 – $83,604 of revenues from customers and $24,028 from Other income] from the Battery Cells and Materials segment.

Revenues from customers increased from $31,159,203 in Q4-2025 to $33,466,068 in Q4-2026. This increase is mainly due to higher volume partially offset by lower tooling revenues.

Other income decreased from $526,720 in Q4-2025 to $439,923 in Q4-2026. The variation is due to grants and refundable tax credits received for Research & Development (“R&D”) programs.

Adjusted EBITDA

      1)   From Advanced Materials, Plastics and Composite Products

The adjusted EBITDA decreased from $2,697,655 in Q4-2025 to $2,049,773 in Q4-2026. The variation is explained as follows:

• Adjusted gross margin on revenues from customers decreased by $96,748 compared to last year due to lower tooling revenues (Q4-2025 higher margins on tooling contract close-out);
• Lower other income of $310,975;
• Higher selling, general & administration expenses and R&D expenses (“Operational expenses”) of $339,159 (excluding Non-operational items of $1,600,000 in Q4-2025).

      2)   From Battery Cells and Materials

The adjusted EBITDA loss improved from $222,276 in Q4-2025 to $141,342 in Q4-2026. The variation is explained by a higher revenue from other income of $224,178 partially offset by lower revenues from customers of $83,604 and higher Operational expenses of $59,640.

B.   RESULTS OF OPERATIONS VARIANCE ANALYSIS – YEARS ENDED

Revenues

	FY 2026	FY 2025	Variation
	$	$	$		%
Revenues from customers	115,037,976	126,363,218	(11,325,242	)	(9	%)
Other income	2,238,333	2,555,170	(316,837	)	(12	%)
Total revenues	117,276,309	128,918,388	(11,642,079	)	(9	%)

All revenues are coming from the Advanced Materials, Plastics and Composite products segment, except for $127,004 of revenues from customers and $1,011,370 from Other income [FY 2025 – $83,604 and $590,936 respectively] coming from the Battery Cells and Materials segment.

Revenues from customers decreased from $126,363,218 in the last year period to $115,037,976 in the current period. This decrease is mainly due to lower volume and tooling revenues.

Other income decreased from $2,555,170 in the last year period to $2,238,333 in the current period. The variation is due to grants and refundable tax credits received for R&D programs.

Adjusted EBITDA

      1)   From Advanced Materials, Plastics and Composite Products

The adjusted EBITDA decreased from $6,847,826 in the last year period to $2,149,114 in the current period. The variation is explained as follows:

• Adjusted gross margin on revenues from customers decreased by $3,690,936 compared to last year due to lower volume and lower tooling revenues;
• Lower Other income of $737,271;
• Higher Operational expenses of $68,505 (excluding non-operational items of $1,600,000 in the last year period).

      2)   From Battery Cells and Materials

The adjusted EBITDA loss improved from a loss of $725,543 in the last year period to $226,908 in the current period. The variation is explained by an increase of revenues from customers and Other income of $43,400 and $420,434 respectively and by lower Operational expenses of $34,801.

C.   OTHER

Additional information about the Corporation, including the Corporation’s Management Discussion and Analysis for the years ended June 30, 2026 and 2025 (“MD&A”) and the Corporation’s consolidated financial statements for the years ended June 30, 2026 and 2025 (the “financial statements”) can be found at www.nanoxplore.ca.

WEBCAST

NanoXplore will hold a webcast today, September 15, 2026, at 5:00 pm EST to review its year ended June 30, 2026. Rocco Marinaccio, CEO and President of NanoXplore, and Pedro Azevedo, Chief Financial Officer, will host the event. To access the webcast please click on the link https://edge.media-server.com/mmc/p/2id33ypn or you can access through our website in the Investors section under Events and Presentations. A replay of this event can be accessed via the above link or on our website.

ABOUT NANOXPLORE INC.

NanoXplore is the world’s largest manufacturer of high-quality, cost-effective graphene, with 4,000 metric tons of annual production capacity in Montreal, Canada. The Company manufactures and supplies high volume graphene powders and provides standard and custom graphene-enhanced plastic and composite products to various customers in transportation, packaging, electronics, and other industrial sectors. The Corporation is also a silicon-graphene enhanced Li-ion battery manufacturer for the energy storage, defense, and industrial markets. The company holds global regulatory approval for unlimited sales volumes of graphene in North America and serves as the lead REACH registrant for graphene in both the EU and the United Kingdom — providing customers with an unmatched combination of scale, quality assurance, and regulatory certainty. NanoXplore is headquartered in Montreal, Quebec with manufacturing facilities in Canada, the United States and Europe.  

Please visit www.nanoxplore.ca

FORWARD-LOOKING STATEMENTS

This press release contains forward-looking statements and forward-looking information (together, “forward-looking statements”) within the meaning of applicable securities laws. All statements, other than statements of historical facts, are forward-looking statements, and subject to risks and uncertainties. All forward-looking statements are based on our beliefs as well as assumptions based on information available at the time the assumption was made and on management’s experience and perception of historical trends, current conditions and expected future developments, as well as other factors deemed appropriate in the circumstances. No assurance can be given that these assumptions and expectations will prove to be correct. Forward-looking statements are not facts, but only predications and can generally be identified by the use of statements that include phrases such as “anticipate, “believe”, “continue”, “could”, “estimate”, “foresee”, “grow”, “expect”, “plan”, “intend”, “forecast”, “future”, “guidance”, “may”, “predict”, “project”, “should”, “strategy”, “target”, “will”, or similar expressions suggesting future outcomes.
Forward-looking information is not a guarantee of future performance and involves a number of risks and uncertainties. Such forward-looking information necessarily involves known and unknown risks and uncertainties, including the relevant assumptions and risks factors set out in NanoXplore’s most recent annual management discussion and analysis filed on SEDAR+ at www.sedarplus.ca, which may cause NanoXplore’s actual results to differ materially from any projections of future results expressed or implied by such forward-looking information. These risks, uncertainties and other factors include, among others, the uncertain and unpredictable condition of global economy, notably as a consequence of the Covid-19 pandemic. Any forward-looking information is made as of the date hereof and, except as required by law, NanoXplore does not undertake any obligation to update or revise any forward–looking statement as a result of new information, subsequent events or otherwise.

Forward-looking statements reflect management’s current beliefs, expectations and assumptions and are based on information currently available to management. Readers are cautioned not to place undue reliance on forward-looking statements, as there can be no assurance that the future circumstances, outcomes or results anticipated or implied by such forward-looking statements will occur or that plans, intentions or expectations upon which the forward-looking statements are based will occur. By their nature, forward-looking statements involve known and unknown risks and uncertainties and other factors that could cause actual results to differ materially from those contemplated by such statements.

No securities regulatory authority has either approved or disapproved the contents of this press release.

For further information, please contact:
        
Pedro Azevedo
Chief Financial Officer
pedro.azevedo@nanoxplore.ca
Tel: 1 438 476-1973

Notification of Transactions by Persons Discharging Managerial Responsibilities and Persons Closely Associated with them

[This form is required for disclosure of transactions under Article 19 of Regulation (EU) No 596/2014 of the European Parliament and of the Council of 16 April 2014 on market abuse (Market Abuse Regulation)] 

1	Details of the person discharging managerial responsibilities/person closely associated
a)	Name	Michael Scott Moore
2	Reason for the notification
a)	Position/status	Chief Operating Officer
b)	Initial Notification Amendment	Initial Notification
3	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	Octave Intelligence plc (“Octave”)
b)	LEI	254900BNJKBGSU9LON27
4	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)	Description of the financial instrument, type of instrument Identification code	Octave class B ordinary shares (“Octave Shares”) with ISIN code IE0003YHD8K8.
b)	Nature of the transaction	Acquisition of Octave Shares
c)	Price(s) and volume(s)
			Price(s)	Volume(s)
			$17.4287	15,000
d)	Aggregated information — Aggregated volume — Price	N/A
e)	Date of the transaction	2026-09-11
f)	Place of the transaction	Nasdaq Stock Market in New York
g)	Additional Information	Octave Shares are listed on the Nasdaq Stock Market in New York under the ticker symbol “OCTV” with the ISIN code IE0003YHD8K8.

Notification of Transactions by Persons Discharging Managerial Responsibilities and Persons Closely Associated with them

[This form is required for disclosure of transactions under Article 19 of Regulation (EU) No 596/2014 of the European Parliament and of the Council of 16 April 2014 on market abuse (Market Abuse Regulation)] 

1	Details of the person discharging managerial responsibilities/person closely associated
a)	Name	Douglas Scott Roark Jr
2	Reason for the notification
a)	Position/status	Vice President Global Finance and Operations
b)	Initial Notification Amendment	Initial Notification
3	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	Octave Intelligence plc (“Octave”)
b)	LEI	254900BNJKBGSU9LON27
4	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)	Description of the financial instrument, type of instrument Identification code	Octave class B ordinary shares (“Octave Shares”) with ISIN code IE0003YHD8K8.
b)	Nature of the transaction	Acquisition of Octave Shares
c)	Price(s) and volume(s)
			Price(s)	Volume(s)
			$17.37	1,000
d)	Aggregated information — Aggregated volume — Price	N/A
e)	Date of the transaction	2026-09-10
f)	Place of the transaction	Nasdaq Stock Market in New York
g)	Additional Information	Octave Shares are listed on the Nasdaq Stock Market in New York under the ticker symbol “OCTV” with the ISIN code IE0003YHD8K8.

 

Conference Call Wednesday, October 28th, at 11:00 A.M.

RALEIGH, N.C., Sept. 15, 2026 (GLOBE NEWSWIRE) — Highwoods Properties, Inc. (NYSE:HIW) will release its third quarter 2026 results on Tuesday, October 27^th, after the market closes.

A conference call will be held the next day, Wednesday, October 28^th, at 11:00 A.M. Eastern time.

For US/Canada callers, dial (833) 461-5787 and enter meeting ID 767718045. International callers should dial (585) 542-9983 and enter the same meeting ID. A live, listen-only webcast can be accessed on the Company’s website at www.highwoods.com through the “Highwoods Properties Q3 2026 Earnings Call” link under the “Investors” section. A replay of the call will also be available on the Company’s website.

About Highwoods
Highwoods Properties, Inc., headquartered in Raleigh, is a publicly-traded (NYSE:HIW), fully-integrated office real estate investment trust (“REIT”) that owns, develops, acquires, leases and manages properties primarily in the best business districts (BBDs) of Atlanta, Charlotte, Dallas, Nashville, Orlando, Raleigh and Tampa. Our vision is to be a leader in the evolution of commercial real estate for the benefit of our customers, our communities and those who invest with us. Our mission is to create environments and experiences that inspire our teammates and our customers to achieve more together. We are in the work-placemaking business and believe that by creating exceptional environments and experiences, we can deliver greater value to our customers, their teammates and, in turn, our shareholders. For more information about Highwoods, please visit our website at www.highwoods.com.

Contact:

Brendan Maiorana                                         Executive Vice President and Chief Financial Officer brendan.maiorana@highwoods.com  919-872-4924

San Antonio, TX, Sept. 15, 2026 (GLOBE NEWSWIRE) — U.S. Global Investors, Inc. (NASDAQ: GROW) (“the Company”), a registered investment advisory firm[1] with expertise in gold mining stocks and the airline industry, is pleased to announce that it will continue its payment of monthly dividends.

The Company’s Board of Directors (the “Board”) approved payment of the $0.0075 per share per month dividend beginning in October 2026 and continuing through December 2026. The record dates are October 12, November 16 and December 14, and the payment dates will be October 26, November 30 and December 28.

Based on the September 11, 2026, closing price of $2.91 this monthly dividend represents an annualized yield of approximately 3.1%.

Travelers Are Spending More Per Trip

The Company notes that across the travel economy, revenue is growing considerably faster than passenger and guest counts, a pattern that points to improving pricing power rather than simple volume recovery. U.S. travel spending reached $122.8 billion in July, running 5.8% ahead of the same month last year, even as air passenger volume an overseas arrivals came in below year-ago level.[2]

The airline data makes the point most clearly. Across 58 carriers, 2025 revenue grew 7.2% on a passenger traffic increase of just 2.5%, driven by higher average fares and a $13.2 billion jump in ancillary revenue, a 13.4% gain. Thirty airlines now book more than a billion dollars annually in ancillary sales, up from 27 the prior year, according to IdeaWorks.[3]

Hotels show the same signature, with revenue per available room climbing 8.2% nationally on room demand growth of 2.8%, and urban properties posting an 8.2% gain of their own at 14.8%.

At the high end, luxury travel bookings for this fall rose 59% while sales rose 69%, with September sales up 77% as affluent travelers move their trips out of the summer crowds.[4]

“We’ve said for years that travel has shifted from a cyclical business to a secular growth story, and the current numbers support that,” said Frank Holmes, Chief Executive Officer and Chief Investment Officer of U.S. Global Investors. “Carriers and hotel operators are earning more from every customer who walks through the door. That is a healthier and more durable form of growth than filling more seats at the same fare, and it tends to show up in margins before it shows up in headlines.”

The Company follows these trends through its specialized funds and its Smart Beta 2.0 quant investment strategy for thematic products. Its U.S. Global Jets ETF (NYSE: JETS) provides investors access to the global airline industry, including airline operators, manufacturers and online travel agencies.

About U.S. Global Investors, Inc.
The story of U.S. Global Investors goes back more than 50 years when it began as an investment club. Today, U.S. Global Investors, Inc. (www.usfunds.com) is a registered investment adviser that focuses on niche markets around the world. Headquartered in San Antonio, Texas, the Company provides investment advisory and other services to U.S. Global Investors Funds and U.S. Global ETFs.

# # #

Please consider carefully a fund’s investment objectives, risks, charges and expenses. For this and other important information, obtain a statutory and summary prospectus for JETS here. Read it carefully before investing.

Investing involves risk, including the possible loss of principal. Shares of any ETF are bought and sold at market price (not NAV), may trade at a discount or premium to NAV and are not individually redeemed from the funds. Brokerage commissions will reduce returns.

Because the funds concentrate their investments in specific industries, the funds may be subject to greater risks and fluctuations than a portfolio representing a broader range of industries. The funds are non-diversified, meaning they may concentrate more of their assets in a smaller number of issuers than diversified funds. The funds invest in foreign securities which involve greater volatility and political, economic and currency risks and differences in accounting methods. These risks are greater for investments in emerging markets. The funds may invest in the securities of smaller-capitalization companies, which may be more volatile than funds that invest in larger, more established companies.

The performance of the funds may diverge from that of the index. Because the funds may employ a representative sampling strategy and may also invest in securities that are not included in the index, the funds may experience tracking error to a greater extent than funds that seek to replicate an index. The funds are not actively managed and may be affected by a general decline in market segments related to the index.

Airline Companies may be adversely affected by a downturn in economic conditions that can result in decreased demand for air travel and may also be significantly affected by changes in fuel prices, labor relations and insurance costs.

Foreign and emerging market investing involves special risks such as currency fluctuation and less public disclosure, as well as economic and political risk. By investing in a specific geographic region, such as China and/or Taiwan, a regional ETFs returns and share price may be more volatile than those of a less concentrated portfolio.

Cargo Companies may be adversely affected by downturn in economic conditions that can result in decreased demand for sea shipping and freight. All opinions expressed and data provided are subject to change without notice. Some of these opinions may not be appropriate to every investor.

This news release may include certain “forward-looking statements” including statements relating to revenues, expenses, and expectations regarding market conditions. These statements involve certain risks and uncertainties. There can be no assurance that such statements will prove accurate and actual results and future events could differ materially from those anticipated in such statements.

The continuation of future cash dividends will be determined by U.S. Global Investors’ Board of Directors, at its sole discretion, after review of the Company’s financial performance and other factors, and is dependent on earnings, operations, capital requirements, general financial condition of the Company, and general business conditions.

Holdings may change daily. Holdings are reported as of the most recent quarter-end. The following securities mentioned in the press release were held by one or more accounts managed by U.S. Global Investors as of (6/30/2026): United Airlines Holdings Inc., Delta Air Lines Inc., American Airlines Group Inc., Southwest Airlines Co., Ryanair Holdings PLC, easyJet PLC, International Consolidated Airlines Group S.A., Deutsche Lufthansa AG, Air France-KLM, Alaska Air Group Inc.

Smart Beta 2.0 is an investment approach that blends the low cost and transparency of passive index tracking with the performance-seeking goals of active management.

All opinions expressed and data provided are subject to change without notice. Some of these opinions may not be appropriate to every investor.

---

[1] Registration does not imply a certain level of skill or training.
[2] U.S. Travel Association, “Travel Insights Dashboard,” 2 September 2026. https://www.ustravel.org/research/travel-recovery-insights-dashboard
[3] IdeaWorksCompany, “2026 SeatMaps.com Yearbook of Ancillary Revenue,” 8 September 2026. https://ideaworkscompany.com/2026-seatmaps-com-yearbook-of-ancillary-revenue-by-ideaworkscompany-report/
[4] Whitten, Sarah. CNBC, 4 September 2026. https://www.cnbc.com/2026/09/04/fall-travel-wealthy-europe.html

Attachment

• Top 10 Airlines Based on Total Ancillary Revenue

CONTACT: Holly Schoenfeldt
U.S. Global Investors, Inc.
210.308.1268
hschoenfeldt@usfunds.com

HIGH POINT, N.C., Sept. 15, 2026 (GLOBE NEWSWIRE) — vTv Therapeutics Inc. (Nasdaq: VTVT), a late-stage biopharmaceutical company focused on the development of cadisegliatin, a novel, potential first-in-class oral adjunctive therapy to insulin being investigated for the treatment of type 1 diabetes (T1D), today announced that it granted 2,500 stock options to purchase shares of common stock to a non-executive employee as a material inducement to employment in accordance with Nasdaq Listing Rule 5635(c)(4).

The stock options that were granted at an exercise price of $31.44 per share. Each option award will vest over a 4-year period, with 25% of the shares underlying the option vesting on the one-year anniversary of the applicable vesting commencement date and the remaining shares thereafter vesting quarterly over the following 36 months, subject to continued employment with vTv on such vesting dates. The options have a term of 10 years and are subject to the terms and conditions of the 2026 Inducement Plan and the stock option agreement covering the grant.

About vTv Therapeutics
vTv Therapeutics is a late-stage biopharmaceutical company focused on developing oral, small molecule drug candidates intended to help treat people living with diabetes and other chronic diseases. vTv’s clinical pipeline is led by cadisegliatin, currently in a US Phase 3 trial, a potential first-in-class oral glucokinase activator being investigated for the treatment of type 1 diabetes. vTv and its development partners are investigating multiple molecules across different indications for chronic diseases. Learn more at vtvtherapeutics.com or follow the company on LinkedIn or X.

About Cadisegliatin
Cadisegliatin (TTP399) is a novel, oral small molecule, liver-selective glucokinase activator being investigated in the US as a potential first-in-class oral adjunctive treatment for type 1 diabetes (T1D). In non-clinical studies, cadisegliatin acted selectively on the liver and increased the activity of glucokinase independently from insulin. These studies support clinical investigation of whether cadisegliatin can improve glycemic control through hepatic glucose uptake and glycogen storage. Cadisegliatin has been granted Breakthrough Therapy designation by the U.S. Food and Drug Administration (FDA).

Cadisegliatin is under investigation, and the safety and efficacy have not been established. There is no guarantee that this product will receive health authority approval or become commercially available for the use being investigated.

Investor Contact
John Fraunces
LifeSci Advisors, LLC
jfraunces@lifesciadvisors.com

Media Contact
Caren Begun
TellMed Strategies
201-396-8551
caren.begun@tmstrat.com

MONTREAL, Sept. 15, 2026 (GLOBE NEWSWIRE) — The Board of Directors of TFI International Inc. (NYSE and TSX: TFII), a North American leader in the transportation and logistics industry, declared a quarterly dividend of US $0.47 per outstanding common share of its capital payable on October 15, 2026 to shareholders of record at the close of business on September 30, 2026.

ABOUT TFI INTERNATIONAL
TFI International Inc. is a North American leader in the transportation and logistics industry, operating across the United States, Canada and Mexico through its subsidiaries. TFI International creates value for shareholders by identifying strategic acquisitions and managing a growing network of wholly-owned operating subsidiaries. Under the TFI International umbrella, companies benefit from financial and operational resources to build their businesses and increase their efficiency. TFI International companies service the following segments:

• Less-Than-Truckload;
• Truckload;
• Logistics.

TFI International Inc. is publicly traded on the New York Stock Exchange and the Toronto Stock Exchange under the symbol TFII. For more information, visit www.tfiintl.com.

For further information:
Alain Bédard
Chairman, President and CEO
TFI International Inc.
647-729-4079
abedard@tfiintl.com

Lisa Pitt, Pharm.D., M.S.J. appointed Senior Vice President, Regulatory Affairs

Shiguang Liu, M.D., Ph.D. appointed Vice President, Clinical Development

REDWOOD CITY, Calif., Sept. 15, 2026 (GLOBE NEWSWIRE) — Jasper Therapeutics, Inc. (Nasdaq: JSPR) (“Jasper”), a clinical stage biotechnology company focused on the design and development of innovative therapies to treat immune-mediated diseases, today announced the appointments of Lisa Pitt, Pharm.D., M.S.J. as Senior Vice President, Regulatory Affairs and Shiguang Liu, M.D., Ph.D. as Vice President, Clinical Development.

“We are excited to have Lisa and Shiguang join us at Jasper following our merger with Kira Pharmaceuticals,” said Jeet Mahal, President and Chief Executive Officer of Jasper. “Lisa’s experience in regulatory affairs at multiple biotech companies and the FDA, along with Shiguang’s expertise in clinical development in rare diseases in renal and metabolic disorders are key additions as we move forward with the development of vensobafusp alfa (KP104), briquilimab and KP701 across a number of immune diseases.”

Dr. Pitt brings over 25 years of experience in leading regulatory and medical affairs across both the industry and at the U.S. Food and Drug Administration (FDA). Most recently, she served as Vice President, Regulatory Affairs at Aiolos Bio prior to its acquisition by GlaxoSmithKline. Prior to that, she held regulatory affairs leadership roles at NorthSea Therapeutics, Horizon Therapeutics, and Viela Bio prior to its acquisition by Horizon Therapeutics. Dr. Pitt served as Senior Regulatory Health Project Manager at the FDA’s Center for Drug Evaluation & Research in the former Division of Gastroenterology and Inborn Errors Products, where she managed the review of Investigation New Drug (IND), New Drug Application (NDA), and Biologic License Application (BLA) submissions. Earlier in her career, she served in Regulatory Affairs roles at AstraZeneca, PAREXEL Consulting, and Novartis. She started her career in laboratory quality assurance roles at Alpharma and Cambridge Biotech. Dr. Pitt received her Pharm.D. from the University of Maryland School of Pharmacy, an M.S.J. from Seton Hall Law School, and a Bachelor degree in Biological Sciences from the University of Delaware, and completed a post-doctoral clinical pharmacy fellowship at Novartis.

Dr. Liu joins after spending over a decade of progressive leadership roles in research and development, pharmacovigilance, and clinical development at Sanofi. Most recently, he served as Clinical Lead and Senior Clinical Research Director with a focus on rare diseases in renal and metabolic disorders and leadership in late-stage clinical trials and regulatory submissions. Prior to joining the biopharmaceutical industry, Dr. Liu held several academic appointments, including Assistant Professor at The Kidney Institute at the University of Kansas Medical Center, research faculty at the Duke University School of Medicine, and Visiting Fellow at the National Institute of Environmental Health Sciences (NIEHS), National Institutes of Health (NIH). Earlier in his career, he was an Associate Professor and Attending Physician at the First Affiliated Hospital of Zhengzhou University Medical School, where he also completed his residency training. Dr. Liu received his M.D. from Zhengzhou University Medical School as well as an M.S. in Medicine and a Ph.D. in Cell Biology from the Chinese Academy of Medical Sciences and Peking Union Medical College.

Material Inducement Grants
Jasper also announced that on September 14, 2026, it granted three new employees options to purchase an aggregate of 243,000 shares of voting common stock (the “Options”) as material inducements to each employee’s employment with Jasper in accordance with Nasdaq Listing Rule 5635(c)(4). The Options were granted pursuant to the Jasper Therapeutics, Inc. Amended and Restated 2022 Inducement Equity Incentive Plan, which was approved by the compensation committee of Jasper’s board of directors on March 14, 2022 and amended and restated on June 2, 2023. The exercise price of each Option is $0.6328. Each Option will vest over four years, with 25% of the total number of shares vesting on the one-year anniversary of the date of commencement of such employee’s employment with Jasper and 1/48th of the total number of shares subject to each Option vesting monthly thereafter, subject in each case to such employee’s continued service to Jasper on each vesting date.

About Jasper
Jasper is a clinical stage biotechnology company focused on the design and development of innovative therapies to treat immune-mediated diseases. Jasper is advancing a pipeline of medicines including KP-104, briquilimab, and KP-701. KP-104 is a potential best-in-class dual-complement inhibitor that has demonstrated positive outcomes in paroxysmal nocturnal hemoglobinuria (PNH) and is under evaluation in other high unmet need nephrology disorders. Briquilimab is an anti-KIT antibody which has demonstrated positive clinical results both as a conditioning agent for stem cell transplant and mast cell mediated diseases such as chronic urticarias and allergic asthma. KP-701, a novel, dual-acting anti-CD79BxCD32B monoclonal antibody (mAb) for autoantibody-mediated disorders currently advancing to the clinic.

Contacts:
Alex Gray (investors)
Jasper Therapeutics
650-549-1454 
agray@jaspertx.com

Argot Partners (investors and media)
kira@argotpartners.com

-Transaction complements Tempest’s existing CD7-targeted lipid nanoparticle in vivo CAR-T delivery platform, which is planned to enter the clinic later this year

-Lead BCMA/GPRC5D dual-targeting in vivo CAR-T candidate is in Phase 1 dose escalation for relapsed/refractory multiple myeloma

-Early clinical observations demonstrate in vivo CAR-T generation and expansion at the current highest evaluable dose, with an initial safety profile supporting continued dose escalation

-Additional pipeline candidates would expand Tempest’s immune reset portfolio across hematologic malignancies and autoimmune diseases

BRISBANE, Calif., Sept. 15, 2026 (GLOBE NEWSWIRE) — Tempest Therapeutics, Inc. (Nasdaq: TPST) (“Tempest”), a clinical-stage biotechnology company developing in vivo CAR-T therapies designed to reset dysfunctional immunity in cancer and autoimmune disease, today announced that it has entered into an exclusive option agreement with Hebei Senlang Biotechnology Co., Ltd. (“Senlang”).

The agreement provides Tempest with an exclusive option to license Senlang’s CD7-targeted lentiviral vector platform and a portfolio of in vivo CAR-T product candidates. The portfolio includes a BCMA/GPRC5D dual-targeting in vivo CAR-T candidate currently in Phase 1 dose escalation for relapsed/refractory multiple myeloma, as well as additional candidates for hematologic malignancies and autoimmune diseases.

“This agreement represents an important step in building Tempest as a multi-platform in vivo CAR-T company focused on immune reset for oncology and autoimmune indications,” said Matt Angel, Ph.D., President and Chief Executive Officer of Tempest. “Upon exercise of the option, the CD7-targeted lentiviral platform would complement our targeted LNP platform, providing two distinct approaches to generating CAR-T cells directly within patients. The lead program is currently in clinical development and has demonstrated in vivo CAR-T generation and expansion, providing encouraging early clinical support.”

Senlang’s proprietary platform uses targeted lentiviral vectors to deliver CAR transgenes to endogenous CD7-positive T cells and natural killer cells, generating CAR-T and CAR-NK cells directly within the patient. The approach is designed to avoid the individualized cell collection and external manufacturing required for conventional autologous CAR-T therapy. The lead program encodes a dual-targeting CAR directed against BCMA and GPRC5D, two clinically validated targets in multiple myeloma. Targeting both antigens may broaden malignant plasma-cell coverage and reduce the potential for tumor escape associated with the loss or downregulation of a single antigen.

The candidate is currently being evaluated in an ongoing Phase 1 dose-escalation study in patients with relapsed/refractory multiple myeloma. Early clinical observations at the current highest evaluable dose demonstrate successful generation and expansion of CAR-T cells in vivo. As of August 25, 2026, no Grade 3 or higher cytokine release syndrome and no immune effector cell-associated neurotoxicity syndrome were observed. The initial safety profile supports continued dose escalation, and patient enrollment and follow-up remain ongoing.

“Together, our targeted LNP and targeted lentiviral vector platforms are intended to support a broad portfolio of immune reset therapies,” said Dr. Angel. “The LNP platform offers a potentially repeatable approach to transient CAR expression, while the lentiviral platform is designed to support durable CAR-cell generation. These complementary capabilities provide Tempest with the flexibility to match the delivery approach to the biology and treatment requirements of different cancers and autoimmune diseases.”

Tempest and Senlang will continue to evaluate the Phase 1 results and the broader product portfolio during the option period. Tempest expects to provide additional information regarding the program as the clinical data mature.

About Senlang’s CD-7-Directed Lentiviral Platform

Senlang has a pipeline of in vivo CAR-T cell programs utilizing its CD7-directed lentiviral platform, which is designed to selectively deliver CAR payloads to endogenous CD7-positive T cells and NK cells, enabling in vivo generation of antigen-directed CAR immune cells. Proprietary nanobody-based retargeting promotes selective cell engagement and efficient transduction, while an engineered detargeted cocal envelope is intended to improve serum resistance, particle stability, and functional delivery in the bloodstream. Producer-cell engineering adds an immune-shielding feature to the lentiviral delivery particles, helping them remain functional longer in the bloodstream and improving delivery to CD7-positive immune cells. In preclinical studies, the platform demonstrated enhanced transduction in whole blood and resting PBMCs, and a single low-dose administration produced efficient in vivo transduction, rapid CAR-cell expansion, tumor-site enrichment, and durable tumor regression in mouse models.

About Tempest Therapeutics

Tempest is a clinical-stage biotechnology company developing next-generation in vivo CAR-T therapies for cancer and autoimmune disease. Tempest’s lead product candidate, TPST-4003, combines a clinically supported dual-targeting CD19/BCMA CAR structure with an advanced CD7-targeting delivery system to support broad immune reset across multiple indications. Tempest envisions a world in which immune reset therapies bring safe, effective, and broadly accessible therapeutic options to patients in need. For additional information, visit Tempest’s website at https://www.tempesttx.com.

About Hebei Senlang Biotechnology

Hebei Senlang Biotechnology Co., Ltd., is a clinical-stage cell therapy company focused on next-generation CAR-T technologies, with specialized expertise in CD7-targeted CAR-T development. Senlang has established end-to-end capabilities spanning CAR design, vector and plasmid development, GMP manufacturing and clinical trial execution, and is currently advancing multiple CD7 CAR-T programs, including a pivotal CD7 CAR-T clinical trial for relapsed or refractory T-cell lymphoblastic lymphoma/leukemia (“T-LBL/ALL”).

Forward-Looking Statements

This press release contains forward-looking statements (including within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and Section 27A of the Securities Act of 1933, as amended, concerning Tempest. These statements may discuss goals, intentions, and expectations as to future plans, trends, events, results of operations or financial condition, or otherwise, based on current beliefs of the management of Tempest, as well as assumptions made by, and information currently available to, management of Tempest. Forward-looking statements generally include statements that are predictive in nature and depend upon or refer to future events or conditions, and include words such as “may,” “will,” “should,” “would,” “could”, “expect,” “anticipate,” “plan,” “likely,” “believe,” “estimate,” “project,” “intend,” “goal”, “suggest”, “target” and other similar expressions. All statements that are not historical facts are forward-looking statements, including but not limited to, statements regarding: Tempest’s exclusive option with Senlang and the advancement, development, design and potential benefits of a BCMA/GPRC5D dual-targeting in vivo CAR-T therapy; the Phase 1 dose escalation trial, including the expected patient population, indications, number of patients, and expected assessments; the potential negotiation and entry into a definitive license agreement with Senlang; the potential ability of BCMA/GPRC5D dual-targeting in vivo CAR-T therapy to enable broad tumor-antigen coverage, strengthen target-cell recognition, and support durable responses; the potential applicability of Tempest’s platform and product candidates across autoimmune and oncology indications; and Tempest’s ability to achieve its operational plans. All forward-looking statements in this press release are based on Tempest’s current expectations, estimates and projections about its industry as well as management’s current beliefs and expectations of future events only as of today and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements. These risks and uncertainties include, but are not limited to Tempest’s need for additional capital to fund its planned programs and operations and to continue to operate as a going concern; unexpected safety or efficacy data observed during preclinical or clinical trials; the possibility that results from prior clinical trials and preclinical studies may not necessarily be predictive of future results; past results may not be indicative of future results; clinical trial site activation or enrollment rates that are lower than expected; loss of key personnel; changes in expected or existing competition; changes in the regulatory environment; risks relating to volatility and uncertainty in the capital markets for biotechnology companies; and unexpected litigation or other disputes. These and other factors that may cause actual results to differ from those expressed or implied are discussed in greater detail in the “Risk Factors” section of Tempest’s Annual Report on Form 10-K for the year ended December 31, 2025, filed with the Securities and Exchange Commission (“SEC”) on March 30, 2026, and in other documents filed by Tempest from time to time with the SEC. Except as required by applicable law, Tempest undertakes no obligation to revise or update any forward-looking statement, or to make any other forward-looking statements, whether as a result of new information, future events or otherwise. These forward-looking statements should not be relied upon as representing Tempest’s views as of any date subsequent to the date of this press release and should not be relied upon as prediction of future events. In light of the foregoing, investors are urged not to rely on any forward-looking statement in reaching any conclusion or making any investment decision about any securities of Tempest.

Investor Contacts:

Sylvia Wheeler
Wheelhouse Life Science Advisors
swheeler@wheelhouselsa.com

Aljanae Reynolds
Wheelhouse Life Science Advisors
areynolds@wheelhouselsa.com

CALGARY, Alberta, Sept. 15, 2026 (GLOBE NEWSWIRE) — Freehold Royalties Ltd. (Freehold) (TSX: FRU) announces that its Board of Directors has declared a dividend of Cdn. $0.09 per common share to be paid on October 15, 2026 to shareholders of record on September 29, 2026.

These dividends are designated as “eligible dividends” for Canadian income tax purposes.

Freehold is uniquely positioned as a leading North American energy royalty company with approximately 6.0 million gross acres in Canada and approximately 1.2 million gross drilling acres in the United States. Freehold’s common shares trade on the Toronto Stock Exchange in Canada under the symbol FRU.

For further information contact

Freehold Royalties Ltd.
Todd McBride, CPA, CMA
Investor Relations
t. 403.221.0833
e. tmcbride@freeholdroyalties.com

Southfield, Michigan, Sept. 15, 2026 (GLOBE NEWSWIRE) — Credit Acceptance Corporation (Nasdaq: CACC) (referred to as the “Company”, “Credit Acceptance”, “we”, “our”, or “us”) announced today that we extended the date on which our $500.0 million revolving secured warehouse facility (the “Facility”) will cease to revolve from September 20, 2027 to September 15, 2028. The interest rate on borrowings under the Facility has been decreased from the Secured Overnight Financing Rate (“SOFR”) plus 185 basis points to SOFR plus 175 basis points.

There were no other material changes to the Facility. As of September 15, 2026, we had $180.0 million outstanding under the Facility.

Additionally, we announced today that we have extended the $500.0 million asset-backed non-recourse secured financing that we entered into on August 28, 2019 (the “Financing”) and to which we refer as Term ABS 2019-2. Under the amendment effecting the extension, the date on which the Financing will cease to revolve has been extended from September 15, 2026 to September 15, 2028. The amendment also increased the interest rate under the Financing from 5.43% to 5.83%.

There were no other material changes to the terms of the Financing.

Description of Credit Acceptance Corporation

We make vehicle ownership possible by providing innovative financing solutions that enable automobile dealers to sell vehicles to consumers regardless of their credit history. Our financing programs are offered through a nationwide network of automobile dealers who benefit from sales of vehicles to consumers who otherwise could not obtain financing; from repeat and referral sales generated by these same customers; and from sales to customers responding to advertisements for our financing programs, but who actually end up qualifying for traditional financing.  

Without our financing programs, consumers are often unable to purchase vehicles, or they purchase unreliable ones. Further, as we report to the three national credit reporting agencies, an important ancillary benefit of our programs is that we provide consumers with an opportunity to improve their lives by improving their credit score and move on to more traditional sources of financing. Credit Acceptance is publicly traded on the Nasdaq Stock Market under the symbol CACC. For more information, visit creditacceptance.com.

CONTACT: Investor Relations: Jay Brinkley
Senior Vice President & Treasurer
(248) 353-2700 Ext. 6739
IR@creditacceptance.com